What is the value of the 21 gene recurrence score in HER2-negative patients?

Journal of Clinical Oncology

Volumn 28, Issue 31, 2010, Pages

  Rosman, Martin ^a   Mylander, W Charles ^a   Tafra, Lorraine ^a  

^a ANNE ARUNDEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN; NITRILE; PROGESTERONE RECEPTOR; RNA; TRIAZOLE DERIVATIVE; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; BREAST TUMOR; CHEMISTRY; CLINICAL TRIAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; NOTE; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; NITRILES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, NEOPLASM; TAMOXIFEN; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 78149258138     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.2280     Document Type: Letter

References (2)

1. Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive post-menopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
2. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 26:1059-1065, 2008